en پاتولوزی دهان، فک و صورت Oral and Maxillofacial Pathology پژوهشي Research <p> <strong>Background </strong>Human papillomavirus (HPV) is a cause of oropharyngeal cancer, but a role for HPV in the etiology of oral cavity squamous cell carcinomas (OCSCC) remains uncertain. </p><p> <strong>Methods</strong> We sought to estimate the etiologic fraction for HPV among consecutive, incident OCSCC diagnosed from 2005 to 2011 at four North American hospitals. DNA and RNA purified from paraffin-embedded tumors were considered evaluable if positive for DNA and mRNA control genes by quantitative PCR. Fifteen high-risk (HR) HPV types were detected in tumors by consensus PCR followed by type-specific HR-HPV E6/7 oncogene expression by quantitative reverse-transcriptase PCR. P16 expression was evaluated by immunohistochemistry (IHC). A study of 400 cases allowed for precision to estimate an etiologic fraction of as low as 0% (97.5% confidence interval, 0–0.92%). </p><p> <strong>Results</strong> Of 409 evaluable OCSCC, 24 (5.9%, 95%CI 3.6–8.2) were HR-HPV E6/7 expression positive 3.7% (95%CI 1.8–5.5) for HPV16 and 2.2% (95%CI 0.8–3.6) for other HR-HPV types. HPV-positive tumors arose from throughout the oral cavity (floor of mouth [n=9], anterior tongue [6], alveolar process [4], hard palate [3], gingiva [1] and lip [1]) and were significantly associated with male gender, small tumor stage, poor tumor differentiation, and basaloid histopathology. P16 IHC had very good-to-excellent sensitivity (79.2%, 95%CI 57.9–92.9), specificity (93.0%, 95%CI 90.0–95.3), and negative-predictive value (98.6%, 95%CI 96.8–99.6), but poor positive-predictive value (41.3%, 95%CI 27.0–56.8) for HR-HPV E6/7 expression in OCSCC. </p><p> <strong>Conclusion</strong> The etiologic fraction for HR-HPV in OCSCC was 5.9%. p16 IHC had poor positive predictive value for detection of HPV in these cancers. </p><hr><p></p><p> <strong>Source: </strong>Journal of Oral Oncology </p><p><a href="http://www.oraloncology.com/article/S1368-8375(12)00229-1/abstract" target="_blank"><font color="#0000ff"> Full Text</font></a> </p> Oral cavity cancer, Human papillomavirus, p16 Immunohistochemistry, In situ hybridization, Predictive value 0 0 http://idai.ir/browse.php?a_code=A-10-32-847&slc_lang=en&sid=1 Mark W. Lingen 10031947532846003661 10031947532846003661 No Department of Pathology, University of Chicago, Chicago, IL, United States Weihong Xiao 10031947532846003662 10031947532846003662 No Viral Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States Alessandra Schmitt 10031947532846003663 10031947532846003663 No Department of Pathology, The Ohio State University Medical Center, Columbus, OH, United States Bo Jiang 10031947532846003664 10031947532846003664 No Viral Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States Robert Pickard 10031947532846003665 10031947532846003665 No Viral Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States Paul Kreinbrink 10031947532846003666 10031947532846003666 No Viral Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States Bayardo Perez-Ordonez 10031947532846003667 10031947532846003667 No Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada Richard C. Jordan 10031947532846003668 10031947532846003668 No Departments of Orofacial Sciences, Pathology & Radiation Oncology, University of California San Francisco, San Francisco, CA, United States Maura L. Gillison 10031947532846003669 10031947532846003669 Yes Viral Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States